Administration of low dose methamphetamine 12h after a severe traumatic brain injury prevents neurological dysfunction and cognitive impairment in rats

Experimental Neurology

Volumn 253, Issue , 2014, Pages 31-40

  Rau, Thomas F ^a   Kothiwal, Aakriti S ^a   Rova, Annela R ^a   Brooks, Diane M ^a   Rhoderick, Joseph F ^a   Poulsen, Austin J ^a   Hutchinson, Jim ^b   Poulsen, David J ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b Montana State Forensic Science Division   (United States)

Author keywords

Methamphetamine; Neuroprotection; Traumatic brain injury

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; METHAMPHETAMINE; NEUROPROTECTIVE AGENT; NEUROTENSIN; STROMAL CELL DERIVED FACTOR 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL DENSITY; CELL LOSS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; EXPERIMENTAL BEHAVIORAL TEST; FOOT FAULT ASSESSMENT; GENE EXPRESSION; INJURY SCALE; MALE; MORRIS WATER MAZE TEST; NERVE FIBER; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRAUMATIC BRAIN INJURY;

METHAMPHETAMINE; NEUROPROTECTION; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; METHAMPHETAMINE; NERVOUS SYSTEM DISEASES; NEUROFILAMENT PROTEINS; NEURONS; RATS; RATS, WISTAR; SPACE PERCEPTION; TIME FACTORS;

EID: 84891924340     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.12.001     Document Type: Article

References (62)

1. Administration F.a.D Desoxyn Product Information 2007.
2. Beauchamp K., et al. Pharmacology of traumatic brain injury: where is the "golden bullet"?. Mol. Med. 2008, 14(11-12):731-740.
3. Blaylock R.L., Maroon J. Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis. Surg. Neurol. Int. 2011, 2(11-12):107.
4. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8(1):57-69.
5. Brown G.C., Neher J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41(2-3):242-247.
6. Cadet J.L., Krasnova I.N. Molecular bases of methamphetamine-induced neurodegeneration. Int. Rev. Neurobiol. 2009, 88:101-119.
7. Charron C., et al. In vivo administration of corticotropin-releasing hormone at remote intervals following ischemia enhances CA1 neuronal survival and recovery of spatial memory impairments: a role for opioid receptors. Behav. Brain Res. 2008, 188(1):125-135.
8. Chen W., S.Z, Wang X.J., Jiang T., Huang Z., Fang D., Zhang D.D. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol. Cell 2009, 34(6):663-673.
9. Coffeen U., et al. Inflammatory nociception diminishes dopamine release and increases dopamine D2 receptor mRNA in the rat's insular cortex. Mol. Pain 2010, 6:75.
10. Cravey B. Introduction to Forensic Toxicology; Rationale of Analytical Method Section 1982, 90-91.
11. Daneshvar D.H., et al. Long-term consequences: effects on normal development profile after concussion. Phys. Med. Rehabil. Clin. N. Am. 2011, 22(4):683-700. (ix).
12. Dempsey K.E., et al. Landstuhl Regional Medical Center: traumatic brain injury screening program. J Trauma Nurs 2009, 16(1):6-7. (10-12).
13. Ding G.L., et al. MRI of neuronal recovery after low-dose methamphetamine treatment of traumatic brain injury in rats. PLoS One 2013, 8(4):e61241.
14. Dolan S., et al. Neuropsychological sequelae of PTSD and TBI following war deployment among OEF/OIF veterans. Neuropsychol. Rev. 2012, 22(1):21-34.
15. Elder G.A., et al. Blast-induced mild traumatic brain injury. Psychiatr. Clin. North Am. 2010, 33(4):757-781.
16. Feeney D.M., Hovda D.A. Amphetamine and apomorphine restore tactile placing after motor cortex injury in the cat. Psychopharmacology (Berl.) 1983, 79(1):67-71.
17. Feeney D.M., Gonzales A., Law W.A. Amphetamine restores locomotor function after motor cortex injury in the rat. Proc. West. Pharmacol. Soc. 1981, 24:15-17.
18. Feeney D.M., Gonzalez A., Law W.A. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982, 217(4562):855-857.
19. Gheysen F., et al. Hippocampal contribution to early and later stages of implicit motor sequence learning. Exp. Brain Res. 2010, 202(4):795-807.
20. Gorchetchnikov A., Grossberg S. Space, time and learning in the hippocampus: how fine spatial and temporal scales are expanded into population codes for behavioral control. Neural Netw. 2007, 20(2):182-193.
21. Grossberg S., Merrill J.W. The hippocampus and cerebellum in adaptively timed learning, recognition, and movement. J. Cogn. Neurosci. 1996, 8(3):257-277.
22. Grossberg S., Seidman D. Neural dynamics of autistic behaviors: cognitive, emotional, and timing substrates. Psychol. Rev. 2006, 113(3):483-525.
23. Gupta S.C., et al. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal. 2012, 16(11):1295-1322.
24. Heitger M.H., et al. Motor deficits and recovery during the first year following mild closed head injury. Brain Inj. 2006, 20(8):807-824.
25. Jin W., et al. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. Mediat. Inflamm. 2008, 2008:725174.
26. Koutmani Y., et al. Corticotropin-releasing hormone exerts direct effects on neuronal progenitor cells: implications for neuroprotection. Mol. Psychiatry 2013, 18(3):300-307.
27. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60(2):379-407.
28. Lee L.L., et al. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp. Neurol. 2004, 190(1):70-78.
29. Li G.Z., et al. Expression of myeloid differentiation primary response protein 88 (Myd88) in the cerebral cortex after experimental traumatic brain injury in rats. Brain Res. 2011, 1396:96-104.
30. Li W., et al. Enhanced cortical expression of myeloid differentiation primary response protein 88 (Myd88) in patients with traumatic brain injury. J. Surg. Res. 2013, 180(1):133-139.
31. Ling H.P., et al. Expression of intestinal myeloid differentiation primary response protein 88 (Myd88) following experimental traumatic brain injury in a mouse model. J. Surg. Res. 2013, 179(1):e227-e234.
32. Lippert-Gruener M., et al. Late effects of enriched environment (EE) plus multimodal early onset stimulation (MEOS) after traumatic brain injury in rats: Ongoing improvement of neuromotor function despite sustained volume of the CNS lesion. Exp. Neurol. 2007, 203(1):82-94.
33. Lloyd E., et al. Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinflammation 2008, 5:28.
34. Luo T., et al. Propofol limits microglial activation after experimental brain trauma through inhibition of nicotinamide adenine dinucleotide phosphate oxidase. Anesthesiology 2013, 119(6):1370-1388.
35. Marklund N., et al. Free radical scavenger posttreatment improves functional and morphological outcome after fluid percussion injury in the rat. J. Neurotrauma 2001, 18(8):821-832.
36. Martin E.M., et al. Traumatic brain injuries sustained in the Afghanistan and Iraq wars. J. Trauma Nurs. 2008, 15(3):94-99. (quiz 100-1).
37. Mendelson J., et al. Human pharmacology of the methamphetamine stereoisomers. Clin. Pharmacol. Ther. 2006, 80(4):403-420.
38. Okie S. Traumatic brain injury in the war zone. N. Engl. J. Med. 2005, 352(20):2043-2047.
39. Ooigawa H., et al. The fate of Nissl-stained dark neurons following traumatic brain injury in rats: difference between neocortex and hippocampus regarding survival rate. Acta Neuropathol. 2006, 112(4):471-481.
40. Otani N., et al. Role of the activated extracellular signal-regulated kinase pathway on histological and behavioral outcome after traumatic brain injury in rats. J. Clin. Neurosci. 2007, 14(1):42-48.
41. Pitkanen A., et al. From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia 2009, 50(Suppl. 2):21-29.
42. Prevention C.f.D.C.a Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006 2006.
43. Rau T.F., et al. Low dose methamphetamine mediates neuroprotection through a PI3K-AKT pathway. Neuropharmacology 2011, 61(4):677-686.
44. Rau T.K., BS, Rova A.R., Brooks D.M., Poulsen D.J. Treatment with low dose methamphetamine improves behavioral and cognitive function after severe traumatic brain injury. J. Trauma Acute Care Surg. 2012, 73(7). (July).
45. Reeves R.R., Panguluri R.L. Neuropsychiatric complications of traumatic brain injury. J. Psychosoc. Nurs. Ment. Health Serv. 2011, 49(3):42-50.
46. S.B. The Merck index: an encyclopedia of chemical, drugs, and biological 1996.
47. Saulle M., Greenwald B.D. Chronic traumatic encephalopathy: a review. Rehabil. Res. Pract. 2012, 2012:816069.
48. Schober M.E., et al. Developmental traumatic brain injury decreased brain derived neurotrophic factor expression late after injury. Metab. Brain Dis. 2012, 27(2):167-173.
49. Semple B.D., et al. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2-/- mice. J. Cereb. Blood Flow Metab. 2010, 30(4):769-782.
50. Semple B.D., Frugier T., Morganti-Kossmann M.C. CCL2 modulates cytokine production in cultured mouse astrocytes. J. Neuroinflammation. 2011, 7:67.
51. Shao W., et al. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via alphaB-crystallin. Nature 2012, 494(7435):90-94.
52. Shultz S.R., et al. Repeated mild lateral fluid percussion brain injury in the rat causes cumulative long-term behavioral impairments, neuroinflammation, and cortical loss in an animal model of repeated concussion. J. Neurotrauma 2012, 29(2):281-294.
53. Sozzani S., et al. Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. J. Immunol. 1994, 152(7):3615-3622.
54. Sozzani S., et al. Synergism between platelet activating factor and C-C chemokines for arachidonate release in human monocytes. Biochem. Biophys. Res. Commun. 1994, 199(2):761-766.
55. Stevens S.L., et al. Reduced cerebral injury in CRH-R1 deficient mice after focal ischemia: a potential link to microglia and atrocytes that express CRH-R1. J. Cereb. Blood Flow Metab. 2003, 23(10):1151-1159.
56. Stoica B.A., Faden A.I. Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics 2010, 7(1):3-12.
57. Thompson H.J., et al. Lateral fluid percussion brain injury: a 15-year review and evaluation. J. Neurotrauma 2005, 22(1):42-75.
58. Vaarmann A., et al. Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis. 2013, 4:e455.
59. Wittenberg G.M., Sullivan M.R., Tsien J.Z. Synaptic reentry reinforcement based network model for long-term memory consolidation. Hippocampus 2002, 12(5):637-647.
60. Xiong Y., Mahmood A., Chopp M. Animal models of traumatic brain injury. Nat. Rev. Neurosci. 2012, 14(2):128-142.
61. Zhang X., et al. Bench-to-bedside review: apoptosis/programmed cell death triggered by traumatic brain injury. Crit. Care 2005, 9(1):66-75.
62. Zhang Z., et al. Immunolocalization of Toll-like receptors 2 and 4 as well as their endogenous ligand, heat shock protein 70, in rat traumatic brain injury. Neuroimmunomodulation 2012, 19(1):10-19.